LOTENSIN

This brand name is authorized in United States. It is also authorized in Poland.

Active ingredients

The drug LOTENSIN contains one active pharmaceutical ingredient (API):

1	Benazepril UNII N1SN99T69T - BENAZEPRIL HYDROCHLORIDE
	Benazepril is a prodrug which, after hydrolysis to the active substance benazeprilat, inhibits the angiotensin-converting enzyme (ACE) and so blocks the conversion of angiotensin I to angiotensin II. This reduces all the effects mediated by angiotensin II – i.e. vasoconstriction and production of aldosterone, which promotes the reabsorption of sodium and water in the renal tubules – and elevates cardiac output.
	Read more about Benazepril

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOTENSIN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA07	Benazepril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
PL	Rejestru Produktów Leczniczych	100039810, 100039826, 100039832
US	FDA, National Drug Code	30698-448, 30698-449, 30698-450